Item 2.02 Results of Operations and Financial Condition. The information provided in Item 7.01 of this Current Report on Form 8-K is incorporated in this Item 2.02 by reference.
TXMD Therapeuticsmd, Inc. - 8-K
Accession
0001213900-26-0365192.027.019.01
Item 2.02 - Results of Operations and Financial Condition
Earnings press release item. The actual results are typically in Exhibit 99.1 - fetch may not have completed.
Item 7.01 - Regulation FD Disclosure
172 words
Item 7.01 Regulation FD Disclosure. On March 30, 2026, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the full year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 and the information contained in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in the filing. The Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in its expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.
Item 9.01 - Financial Statements and Exhibits
49 words
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Index Exhibit No. Description 99.1 Press Release from TherapeuticsMD, Inc., dated March 30, 2026, entitled “TherapeuticsMD Announces Full Year 2025 Financial Results” 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document). 1